1. Wood RA, Berger M, Dreskin SC, Setse R, Engler RJ, Dekker CL, et al. An algorithm for treatment of patients with hypersensitivity reactions after vaccines. Pediatrics. 2008; 122:e771–e777.
Article
2. Busse JW, Morgan L, Campbell JB. Chiropractic antivaccination arguments. J Manipulative Physiol Ther. 2005; 28:367–373.
Article
3. Ruggeberg JU, Gold MS, Bayas JM, Blum MD, Bonhoeffer J, Friedlander S, et al. Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2007; 25:5675–5684.
Article
4. Fritsche PJ, Helbling A, Ballmer-Weber BK. Vaccine hypersensitivity-update and overview. Swiss Med Wkly. 2010; 140:238–246.
5. Kim BY, Kim DH, Lee HJ, Jung SK, Li XS, Go UY, et al. Investigation on the frequency and severity of common adverse reactions of Japanese encephalitis Vaccines. Korean J Pediatr Infect Dis. 2009; 16:183–190.
Article
6. Shin WJ, Kim SY, Ahn YM. Follow-up study of children with egg allergy : comorbidity of allergic diseases and factors affecting prognosis. Pediatr Allergy Respir Dis. 2004; 14:87–96.
7. Lee K, Lee S. Two children with egg allergy who developed systemic side reaction with MMR vaccine. Pediatr Allergy Respir Dis. 1998; 8:280–285.
8. Zent O, Arras-Reiter C, Broeker M, Hennig R. Immediate allergic reactions after vaccinations--a post-marketing surveillance review. Eur J Pediatr. 2002; 161:21–25.
Article
9. The Korean Pediatric Society. Immunization guideline. 7th ed. Seoul: The Korean Pediatric Society;2012. p. 7–8.
10. Fiore AE, Uyeki TM, Broder K, Finelli L, Euler GL, Singleton JA, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep. 2010; 59(RR-8):1–62.
11. Roh EJ, Chung EH, Kim JK. Quantitative analysis of egg protein by ELISA in distributed influenza vaccine in Korea. Pediatr Allergy Respir Dis. 2009; 19:345–353.
12. Kelso JM, Greenhawt MJ, Li JT, Nicklas RA, Bernstein DI, Blessing-Moore J, et al. Adverse reactions to vaccines practice parameter 2012 update. J Allergy Clin Immunol. 2012; 130:25–43.
Article
13. Lee DH, Shin SS, Jun BY, Lee JK. National level response to pandemic (H1N1) 2009. J Prev Med Public Health. 2010; 43:99–104.
Article
14. Kim SY, Cho J, Cha SH, Bae CW. Current status of production and market of human vaccine products in Korea. Clin Exp Vaccine Res. 2013; 2:120–127.
Article
15. Babl FE, Lewena S, Brown L. Vaccination-related adverse events. Pediatr Emerg Care. 2006; 22:514–519.
Article
16. Rona RJ, Keil T, Summers C, Gislason D, Zuidmeer L, Sodergren E, et al. The prevalence of food allergy: a meta-analysis. J Allergy Clin Immunol. 2007; 120:638–646.
Article
17. Sicherer SH. Epidemiology of food allergy. J Allergy Clin Immunol. 2011; 127:594–602.
Article
18. Ross MP, Ferguson M, Street D, Klontz K, Schroeder T, Luccioli S. Analysis of food-allergic and anaphylactic events in the National Electronic Injury Surveillance System. J Allergy Clin Immunol. 2008; 121:166–171.
Article
19. James JM, Burks AW, Roberson PK, Sampson HA. Safe administration of the measles vaccine to children allergic to eggs. N Engl J Med. 1995; 332:1262–1266.
Article
20. Herman JJ, Radin R, Schneiderman R. Allergic reactions to measles (rubeola) vaccine in patients hypersensitive to egg protein. J Pediatr. 1983; 102:196–199.
Article
21. Mullins R, Kemp A, Gold M. Influenza vaccination of the egg-allergic individual. Med J Aust. 2010; 193:254–255.
Article
22. Des Roches A, Paradis L, Gagnon R, Lemire C, Begin P, Carr S, et al. Egg-allergic patients can be safely vaccinated against influenza. J Allergy Clin Immunol. 2012; 130:1213–1216.e1.
Article
23. Yavuz ST, Sahiner UM, Sekerel BE, Tuncer A, Kalayci O, Sackesen C. Anaphylactic reactions to measles-mumps-rubella vaccine in three children with allergies to hen's egg and cow's milk. Acta Paediatr. 2011; 100:e94–e96.
Article
24. Fischer M, Lindsey N, Staples JE, Hills S. Centers for Disease Control and Prevention (CDC). Japanese encephalitis vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010; 59(RR-1):1–27.
25. Kwittken PL, Rosen S, Sweinberg SK. MMR vaccine and neomycin allergy. Am J Dis Child. 1993; 147:128–129.
Article
26. National Center for Immunization and Respiratory Diseases. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2011; 60:1–64.
27. Russell M, Pool V, Kelso JM, Tomazic-Jezic VJ. Vaccination of persons allergic to latex: a review of safety data in the Vaccine Adverse Event Reporting System (VAERS). Vaccine. 2004; 23:664–667.
Article
28. Centers for Disease Control and Prevention (CDC). FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2010; 59:626–629.
29. Grotto I, Mandel Y, Ephros M, Ashkenazi I, Shemer J. Major adverse reactions to yeast-derived hepatitis B vaccines: a review. Vaccine. 1998; 16:329–334.
Article
30. DiMiceli L, Pool V, Kelso JM, Shadomy SV, Iskander J. V.A.E.R.S. Team. Vaccination of yeast sensitive individuals: review of safety data in the US vaccine adverse event reporting system (VAERS). Vaccine. 2006; 24:703–707.
Article
31. Cox NH, Forsyth A. Thiomersal allergy and vaccination reactions. Contact Dermatitis. 1988; 18:229–233.
Article
32. Zheng W, Dreskin SC. Thimerosal in influenza vaccine: an immediate hypersensitivity reaction. Ann Allergy Asthma Immunol. 2007; 99:574–575.
Article
33. Lee-Wong M, Resnick D, Chong K. A generalized reaction to thimerosal from an influenza vaccine. Ann Allergy Asthma Immunol. 2005; 94:90–94.
Article
34. Kattan JD, Konstantinou GN, Cox AL, Nowak-Węgrzyn A, Gimenez G, Sampson HA, et al. Anaphylaxis to diphtheria, tetanus, and pertussis vaccines among children with cow's milk allergy. J Allergy Clin Immunol. 2011; 128:215–218.
Article
35. Israeli E, Agmon-Levin N, Blank M, Shoenfeld Y. Macrophagic myofaciitis a vaccine (alum) autoimmune-related disease. Clin Rev Allergy Immunol. 2011; 41:163–168.
Article
36. Jefferson T, Rudin M, Di Pietrantonj C. Adverse events after immunisation with aluminium-containing DTP vaccines: systematic review of the evidence. Lancet Infect Dis. 2004; 4:84–90.
Article
37. Coors EA, Seybold H, Merk HF, Mahler V. Polysorbate 80 in medical products and nonimmunologic anaphylactoid reactions. Ann Allergy Asthma Immunol. 2005; 95:593–599.
Article
39. Brotherton JM, Gold MS, Kemp AS, McIntyre PB, Burgess MA, Campbell-Lloyd S, et al. Anaphylaxis following quadrivalent human papillomavirus vaccination. CMAJ. 2008; 179:525–533.
Article
40. Kang LW, Crawford N, Tang ML, Buttery J, Royle J, Gold M, et al. Hypersensitivity reactions to human papillomavirus vaccine in Australian schoolgirls: retrospective cohort study. BMJ. 2008; 337:a2642.
Article
41. Macartney KK, Chiu C, Georgousakis M, Brotherton JM. Safety of human papillomavirus vaccines: a review. Drug Saf. 2013; 36:393–412.
Article
42. Chang S, O'Connor PM, Slade BA, Woo EJ. U.S. Postlicensure safety surveillance for adolescent and adult tetanus, diphtheria and acellular pertussis vaccines: 2005-2007. Vaccine. 2013; 31:1447–1452.
Article
43. The Korean Pediatric Society. Immunization guideline. 7th ed. Seoul: The Korean Pediatric Society;2012. p. 265.
44. The Korean Pediatric Society. Immunization guideline. 7th ed. Seoul: The Korean Pediatric Society;2012. p. 18–19.
45. Zeiger RS. Current issues with influenza vaccination in egg allergy. J Allergy Clin Immunol. 2002; 110:834–840.
Article
46. Erlewyn-Lajeunesse M, Brathwaite N, Lucas JS, Warner JO. Recommendations for the administration of influenza vaccine in children allergic to egg. BMJ. 2009; 339:b3680.
Article